A Phase 3 Study to Evaluate the Efficacy and Safety of TAK-390MR (60 mg Once-Daily [QD] and 90 mg QD) and an Active Comparator, Lansoprazole (30 mg QD) on Healing of Erosive Esophagitis.

Trial Profile

A Phase 3 Study to Evaluate the Efficacy and Safety of TAK-390MR (60 mg Once-Daily [QD] and 90 mg QD) and an Active Comparator, Lansoprazole (30 mg QD) on Healing of Erosive Esophagitis.

Completed
Phase of Trial: Phase III

Latest Information Update: 04 Mar 2016

At a glance

  • Drugs Dexlansoprazole (Primary) ; Lansoprazole
  • Indications Erosive oesophagitis
  • Focus Therapeutic Use
  • Sponsors Takeda
  • Most Recent Events

    • 30 Sep 2013 Post-hoc pooled analysis published in Alimentary Pharmacology and Therapeutics.
    • 11 May 2009 Primary endpoint 'Lesion healing' has been met.
    • 11 May 2009 Results have been reported in Alimentary Pharmacology and Therapeutics.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top